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Background: To assess the cost-effectiveness of trabectedin compared with end-stage treatment (EST) after failure
with anthracycline and/or ifosfamide in metastatic soft tissue sarcoma (mSTS).
Design: Analysis was carried out using a probabilistic Markov model with trabectedin / EST and EST arms, three
health states (stable disease, progressive disease and death) and a lifetime perspective (3% annual discount rate).
Finnish resources (drugs, mSTS, adverse events and travelling) and costs (year 2008) were used. Efﬁcacy was based
on an indirect comparison of the STS-201 and European Organisation for Research and Treatment of Cancer trials.
QLQ-C30 scale scores were mapped to 15D, Short Form 6D and EuroQol 5D utilities. The outcome measures were
the cost-effectiveness acceptability frontier, incremental cost per life year gained (LYG) and quality-adjusted life year
(QALY) gained and the expected value of perfect information (EVPI).
Results: Trabectedin / EST was associated with 14.0 (95% conﬁdence interval 9.1–19.2) months longer survival,
€36 778 higher costs (€32 816 using hospital price for trabectedin) and €31 590 (€28 192) incremental cost per LYG
with an EVPI of €3008 (€3188) compared with EST. With a threshold of €50 000 per LYG, trabectedin / EST had
98.5% (98.2%) probability of being cost-effective. The incremental cost per QALY gained with trabectedin / EST was
€42 633–47 735 (€37 992–42 819) compared with EST. The results were relatively insensitive to changes.
Conclusion: Trabectedin is a potentially cost-effective treatment of mSTS patients.
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key ﬁndings
Trabectedin improved survival signiﬁcantly. Trabectedin
followed by end-stage treatment (EST) was estimated to result
to 14 months of additional survival and 9–10 months of
additional quality-adjusted survival [quality-adjusted life years
(QALY) gained] compared with EST alone in metastatic soft
tissue sarcoma (mSTS) patients who have previously received
anthracycline and/or ifosfamide. Trabectedin had an impact on
mortality that continued beyond the active trabectedin
treatment.
Trabectedin was a potentially cost-effective second-line
treatment of mSTS. Trabectedin resulted to €31 590 (€28 192
using hospital price for trabectedin) incremental cost per
additional year of life gained and to €42 633–47 735 (€37 992–
42 819) cost per additional QALY gained compared with EST.
With a threshold of €50 000 per life year gained (LYG),
trabectedin had 98.5% (98.2%) probability of being cost-
effective.
Results were relatively insensitive to changes in the key
parameters. Based on the maximum expected value of perfect
information estimate of €3008 (€3188 using the hospital price
for trabectedin), the value of additional parameter information
is likely to be low.
background
Soft tissue sarcomas (STS) are rare tumours that account for
1% of all adult cancers. The annual incidence of STS is 1–3/
100 000 [1]. Approximately 50%–80% of STS metastasise [2,
3]. Complete surgical resection is rarely accomplished.
Therefore, the main treatment of mSTS is systemic
chemotherapy (CT) [1, 2, 4], but the role of (neo)adjuvant CT
has remained controversial [2]. The standard ﬁrst-line
treatments for mSTS are anthracycline and ifosfamide alone or
in combination (A/I [1, 5]). After progression of STS, there are
currently no standard therapies.
Trabectedin (TRA) induces tumour regression and inhibits
tumour growth [6]. TRA has produced clinical beneﬁts in
ovarian cancer, breast cancer and sarcoma [7]. Recent studies
have shown that TRA arrests STS growth in 40%–60% of
tumours [8–11] and produces signiﬁcant clinical beneﬁt in
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clinically, TRA is well tolerated [12]. The safety and efﬁcacy of
TRA shown in clinical trials have been conﬁrmed in
compassionate use [8].
The objective of this study was to present the cost-
effectiveness of TRA followed by EST (TRA / EST) against
EST alone as second-line treatments in patients with STS. The
results were presented as incremental cost-effectiveness ratios
(ICER), probability of cost-effectiveness and the value of
information (VOI). ICER is deﬁned as
ICER=
D C
D E
=
 C12 C0
 E12 E0
;
where  C stands for average costs and  E for average health
beneﬁts (subscripts indicate treatment; 1 is new and 0 is
current). ICER characterises the marginal value of treatments in
the form of additional cost per additional unit of health beneﬁt
gained or saved during given perspective. In this study, ICERs
are produced separately for LYG and QALY gained in a lifelong
perspective. The probability of cost-effectiveness was assessed
with the cost-effectiveness acceptability frontier (CEAF) and
VOI with the expected value of perfect information (EVPI).
materials and methods
patients, treatments and timeframe
The modelled study population consisted of adult patients with mSTS who
were previously treated with A/I. The population deﬁnition followed the
indication of TRA.
Because current evidence does not support any other CTs for mSTS, TRA
treatment (24-h infusion every 21 days) was compared with EST initiated
immediately after failure with A/I. EST comprises multiple treatment
alternatives. This approach was supported by oncological experts and the
literature [1, 13].
Analysis was carried out from a health care payer perspective
(productivity losses, income transfers and value added taxes were excluded)
including costs of drugs, mSTS, serious adverse event (SAE) treatment and
travelling. The analyses were based on a lifetime duration where the model
was run for a total of 60 monthly cycles, i.e. 5 years.
model structure and simulation
A simpliﬁed schematic picture of the model structure is presented in
Figure 1. The model started at the point where the treatment with A/I
failed. In the model, one cohort was treated with TRA and the other with
EST. Patients on TRA could have a treatment response [have a stable
disease (SD)], disease progression (PD) or they could die. Patients on EST
stayed in PD until death.
The Excel model is based on a probabilistic approach (Monte Carlo
simulation [14]) that allows the characterisation of multiple parameter
uncertainty (i.e. distributions rather than simple means were modelled).
The model applies monthly cycles due to the nature of clinical data. In
reality, the treatment cycles of CTs are usually 3 weeks. Half-cycle
correction was used (i.e. half of the costs and effects related to the last cycle
were accrued, if patient changed health state), but CT-related costs were not
corrected as the model assigned all drug costs in the ﬁrst cycle.
efﬁcacy data
The primary outcome of treatment efﬁcacy was life expectancy. In the
model, the efﬁcacy differences were conveyed through transition
probabilities. The clinical efﬁcacy, i.e. transition probabilities for staying in
a health state or transitioning to another health state, in the TRA arm were
taken from STS-201 [9], while the transition probabilities used in the EST
arm were obtained from the European Organisation for Research and
Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC
STBSG) trial [15, 16] patient level data. The estimation of transition
probabilities is presented in Appendix 1.
The use of the historical EORTC STBSG dataset for the EST arm had
inherent limitations. However, those studies using ifosfamide [15, 16] were
conducted with similar eligibility criteria and efﬁcacy end points as STS-
201. Other studies that investigated the efﬁcacy and safety of drugs not
Figure 1. Model structure and health states. A/I, anthracycline and/or ifosfamide; EST, end-stage treatment; M, Markov chain; mSTS, mestastatic soft tissue
sarcoma; PD, progressive disease; SD, stable disease; TRA, trabectedin.
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hindered by poor follow-up (compare Le Cesne et al. [12]). Since the
period of interest was the duration PD / death, poor follow-up could have
biased the results. However, among sensitivity analyses, patients receiving
active EST (33%) were assumed to experience disease stabilisation for 6
months based on dacarbazine (DAC) results [17]. This seems to be a fair
estimate for active EST [2].
probabilistic parameters
The probabilistic approach examines parameter uncertainty using
distributions around key parameters [14] in the model and relaxes the
assumption of linearity typical for the deterministic (point estimate)
approach. Speciﬁcally, the probabilistic approach included TRA cycles, TRA
dose intensity and transition probabilities. The transition probabilities were
averaged >1000 simulations to determine the mean transition probabilities
[b, 95% conﬁdence intervals (CIs)] for the TRA / EST arm: remaining SD
0.8476 (0.7741–0.9121), SD / PD 0.1457 (0.0840–0.2159), SD / death
0.0067 (0.0039–0.0100) and PD / death 0.1118 (0.0735–0.1570) and for
the EST arm: remaining PD 0.8870 (0.8430–0.9265) and PD / death
0.1118 (0.0735–0.1570).
resource use and costs
Resources and costs are presented in detail in Appendix 2. TRA’s dose
intensity was 1.17 mg/m
2 in STS-201 and the average body surface area
(BSA) was 1.80 m
2, which results in 2.10 mg per administration (TRA 1.50
mg/m
2 and BSA of 1.70 m
2 were assumed in a sensitivity analysis scenario).
Given the TRA vial sizes, patients were conservatively assumed to receive
two 1-mg vials and one 0.25-mg vial per administration. This included drug
wastage (0.15 mg), which can be avoided if infusions are given at the same
time for many patients. Average drug cost based on the average of 5.0 TRA
cycles in STS-201 was applied equally to all patients in the TRA arm in the
ﬁrst modelling cycle. Conservatively, patients who progress before ﬁve
cycles with TRA will accrue ﬁve cycles worth of costs.
Despite the lack of approved CTs (except TRA) after A/I exhaustion,
further CTs are commonly initiated [1, 13]. Conservatively, only 33% of
patients were assumed to receive active CT during EST. The type of off-
label CT administered at this stage varies based on, e.g., patient toleration
and the histology of disease. In the base case, further CT was assumed to be
based on etoposide (ETO) and DAC (67% and 33%, respectively). The
impacts of these EST assumptions were tested in sensitivity analyses. In the
EST arm, the excepted EST CT costs were applied to patients at the
beginning of the model and, in the TRA / EST arm, the excepted EST CT
costs were applied once patients transited to PD.
After A/I failure, patients consume a variety of resources [13]. There were
no Finnish data available on the ongoing costs after A/I failure. Thus, costs
of metastatic renal cell carcinoma (mRCC) treatment from two Finnish
hospital settings [18] were used because these patients were also without
efﬁcient treatments, both mSTS and mRCC have similar progression
patterns and imaging examinations and clinician visits of mSTS and mRCC
patients seem to be relatively comparable [13, 18]. The sensitivity of this
assumption was tested by using UK mSTS costs [13].
Finnish unit costs [19] indexed to the year 2008 using ofﬁcial health care
index were used to estimate the administration costs of TRA and treatment
of SAEs. Conservatively, all TRA patients were assumed to be treated on an
inpatient basis in cancer clinic (outpatient administration is presented as
a sensitivity analysis scenario) and the administration costs were applied in
the ﬁrst cycle of the model. Though TRA was well tolerated in STS-201, the
model accounts for the cost impact of seven SAEs related to drugs that led
to hospitalisation. Since vomiting and nausea were common, it was
assumed that the cost of inpatient treatment of gastroenteritis was an
appropriate proxy for the SAE treatment cost. No costs for treating any
SAEs were applied in the EST arm and no death costs were assumed. The
impacts of death and TRA SAE costs were explored among sensitivity
analyses.
utilities
Incremental cost per LYG does not include the quality of survival, and thus,
it falls short of a measure that can be more readily assessed against other
health care interventions, such as the cost per QALY gained. A systematic
search of the literature yielded no data on the generic quality of life (QoL)
associated with the STS health states used in the model. Thus, the disease-
speciﬁc scale score results of EORTC QoL questionnaire (QLQ-C30) by
Poveda et al. [20] in mSTS population were mapped to 15D [21], Short
Form 6D (SF-6D [22]) and EuroQol 5D (EQ-5D [23]) generic QoL index
values using the ordinary least-squares regression equations on
Kontodimopoulos et al. [24]. The numbers used in the estimation are
presented in Appendix 3.
The average expected QoL indexes based on 15D, SF-6D and EQ-5D
were 0.736, 0.668 and 0.654, respectively. QoL was set to 0 for death.
SAEs produced by TRA were taken into account by assuming a disutility
(QoL decrease) of 0.200 per SAE. No disutilities due to EST SAEs were
included.
sensitivity analysis
As the base case analysis was probabilistic and explored the effect of
multivariate parameter uncertainty, ﬁgures presenting simulated ICERs as
cost-effectiveness plane (CEP) and CEAF based on the probabilistic
sensitivity analysis were appealing. Percentile method was used to derive
CIs from the 1000 probabilistic simulation results. CEAF illustrates the
sensitivity of the conclusion of cost-effectiveness to various thresholds of
acceptability that a payer may hold, recognises the uncertainty of the
generated cost-effectiveness estimate and presents the optimal treatment
options [25] that have the highest expected net monetary beneﬁt (NMB =
E · willingness to pay 2 C).
CEAF does not consider the consequences of a wrong decision or VOI.
Thus, per patient EVPI was estimated [14, 25], which combines both the
probability of wrong decision and the consequences of that wrong decision
as NMB forgone. The EVPI estimate also represents the value of parameter
uncertainty that could be resolved by acquiring additional research evidence
for model parameters (i.e. how much would be reasonable to invest for
a new study at patient level given the willingness to pay, if parameter
uncertainty needs to be decreased and willingness to pay means the
acceptable cost for beneﬁt).
In addition, the following scenarios were simulated
 Discounting not employed
 Ongoing costs based on UK mSTS cost data from Judson et al. [13]:
€2320.26 (€2511.76 in 2008 value) for 119 days (€633.22 per cycle in 2008
value, £1 = €1.153245)
 Death costs included based on Judson et al. [13] mSTS cost data: €566.70
(€618.27 in 2008 value) per patient
 0%, 20% or 50% receive active EST
 TRA wholesale/hospital price (in hospital €1994.00 per 1 mg and €530.00
per 0.25 mg)
 TRA as outpatient (ambulatory pumps)
 TRA dose intensity of 1.50 mg/m
2 and BSA of 1.70 m
2
 TRA SAE costs doubled
 ETO monotherapy 120 mg/m
2 days 1, 3 and 5; every 21 days as EST
 DAC monotherapy 250 mg/m
2 days 1–5; every 21 days as EST
 IADIC; doxorubicin 50 mg/m
2 day 1, ifosfamide 1 g/m
2 with mesna 40
mg/kg days 1–5 and DAC 250 mg/m
2 days 1–5; very 21 days as EST
 IE; ifosfamide 1 g/m
2 with mesna 40 mg/kg days 1–5, ETO 100 mg/m
2
days 1, 3, 5, phenobarbital 100 mg p.o. days 0–6 and growth hormone;
every 21 days as EST
Annals of Oncology original article
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2 with mesna 40 mg/kg days 1–5, ETO 100
mg/m
2 days 1–3, methotrexate 30 mg/m
2 days 3 and 10; every 21 days
as EST
 Patients on active EST (33%) experience disease stabilisation for 6
months [17] in both EST groups or in EST-only group
 All patients treated with EST receive active treatment and EST alone
patients experience disease stabilisation for 6 months [17]. Actually, this
is TRA versus ETO/DAC setting, which conservatively assumes no
additional beneﬁt with active EST after TRA.
results
According to the STS-201 and EORTC STBSG data analysis, the
transition probability of PD / death in TRA naive patients
was higher than that of death for those patients who were
treated with TRA. Once a TRA-treated patient progressed
after SD, the probability of death increased markedly, but
it remained lower than for those patients who were TRA
naive.
effectiveness and costs
TRA / EST had both a statistically and clinically signiﬁcant
advantage over EST in terms of mean overall survival (OS):
21.1 (95% CI 16.2–26.4) versus 7.2 (95% CI 6.4–8.1) months,
respectively, in mSTS patients who received priory A/I
(Table 1). The extra months TRA / EST patients survived
compared with EST patients were 14.0 (95% CI 9.1–19.2), i.e.
1.16 (95% CI 0.76–1.60) LYGs.
Based on the QoL tool, TRA / EST resulted to the quality-
adjusted survival of 1.16–1.30 QALYs and the respective QALY
amount due to EST was 0.39–0.44 QALYs (Table 1).
Consequently, the lowest QALYs gained due to TRA / EST
compared with EST was 0.77 (95% CI 0.55–1.04) based on EQ-
5D and the highest 0.86 (95% CI 0.61–1.16) based on 15D. The
15D results were also most credible based on Kontodimopoulos
et al. [24].
Expected lifetime costs for TRA / EST were €44 346 (95%
CI €34 073–56 269) assuming the pharmacy retail price for
TRA and €40 384 (95% CI €31 282–50 247) assuming the
hospital price for TRA. EST resulted in €7568 (95% CI €7129–
8158) lifetime costs (hospital prices assumed). Consequently,
the incremental cost of TRA / EST compared with EST was
€36 778 (95% CI €26 397–48 801) assuming the pharmacy
retail price for TRA and €32 816 (95% CI €23 315–42 317)
assuming the hospital price for TRA.
cost-effectiveness
The use of TRA / EST in mSTS patients was associated with
an incremental cost of €31 590 (95% CI €21 279–47 630) per
LYG compared with EST when the pharmacy retail price for
TRA was assumed. The correspondent result was €28 192 (95%
CI €16 833–39 551) with the wholesale/hospital price for TRA.
The cost for a QALY gained with TRA / EST compared with
EST was €42 633–47 735 based on the pharmacy retail price of
TRA and €37 992–42 819 based on the hospital price for TRA,
depending on the utility tool. The cost-utility based on SF-6D
and EQ-5D was almost equivalent, whereas the 15D-based
results were €5000 lower (Table 1).
sensitivity analysis
CEP is presented in Figure 2 and CEAF in Figure 3. According
to CEP, TRA provides signiﬁcant gain in life years with
signiﬁcantly higher costs. However, the uncertainty related to
ICER is not signiﬁcant with the generally approved ICER
thresholds: according to CEAF, the 50%, 75%, 90% and 95%
probabilities of cost-effectiveness for TRA / EST were
obtained with the willingness to pay (WTP) levels of €31 797,
€36 445, €41 534 and €44 967 per LYG when TRA had the
pharmacy retail price (€28 464, €33 461, €38 755 and €43 058
per LYG with the hospital price for TRA), respectively.
The highest EVPI estimate was obtained with the ICER value,
which was equivalent to the change of optimal treatment in the
CEAF from EST to TRA / EST (Figure 3). With the WTP of
€31 590 (€28 192 assuming the hospital price for TRA) per
LYG, the EVPI estimate was €3008 (€3188). With WTP levels of
€30 000, €40 000 and €50 000 per LYG, the respective EVPI
estimates were €2101, €566 and €75 (€2328, €374 and €59 with
the hospital price for TRA).
Generally, the results were robust to changes in the key
parameters. For example, when all patients treated with EST
were assumed to receive off-label active CT treatment and EST
alone patients were assumed to experience disease stabilisation
for 6 months (TRA versus ETO/DAC setting), the result was
€33 830 (95% CI €22 237–55 822) per LYG. Yet, the results
were somewhat sensitive to the administered dose and price of
TRA (Table 1). The increase of TRA to the recommended dose
in place of that actually observed in STS-201 resulted to
€35 849 (95% CI €26 479–52 164) per LYG (TRA’s pharmacy
retail price assumed). This was unrealistic, as the base case
scenario accounted for dose reductions and withdrawals, which
were expected with CTs. When the pharmacy premium was
excluded from the price of TRA and the hospital/wholesale
price was used, the incremental cost per LYG decreased to
€28 192. This can be more readily applicable in countries where
the pharmacy premium is low or when TRA is used in the
public hospital settings in Finland.
discussion
TRA / EST results in a signiﬁcantly higher OS than EST, but
with higher costs. Thus, we asked whether TRA / EST is
a cost-effective second-line treatment of mSTS patients.
TRA slowed progression and had an impact on mortality that
continued beyond the TRA treatment. The incremental cost per
LYG and QALY gained were €31 590 and €42 633–47 735 for
TRA / EST versus EST when the pharmacy retail price for
TRA was assumed, respectively, which indicate that TRA /
EST was potentially cost-effective. The results were in line with
the previous cost-effectiveness results obtained in the Finnish
setting [17, 26, 27]. When the wholesale/hospital price was
assumed for TRA, the incremental cost per LYG and QALY
gained was €28 192 and €37 992–42 819, which are more
applicable in countries with lower pharmacy premium (e.g.
Sweden) or in the Finnish public hospital setting. Also the
highest EVPI estimate per patient was relatively low €3008
(€3188 assuming the hospital price for TRA) compared with
the total per patient costs, meaning that gathering additional
original article Annals of Oncology
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presented in this study may have little impact on the results.
The results were most sensitive to the administered dose and
price of TRA. None of the other sensitivity analyses showed
a marked effect on the cost-effectiveness and probabilistic
approach took into account the relatively small sample sizes of
STS-201 and EORTC STBSG. mSTS also lacked generic QoL
data. Given STS is an orphan disease, however, this is
unsurprising. Though utilities were estimated using mapping
and the impact of QoL was tested using different tools, these
Table 1. Results of base case cost-effectiveness, sensitivity and CUA
Cost-effectiveness scenarios Costs (€) Life years ICER
TRA EST Incr. TRA EST Incr.
Base case, TRA’s retail
price (SE)
44 346 (11 324) 7568 (525) 36 778 (11 431) 1.760 (0.438) 0.596 (0.072) 1.164
a (0.429) 31 590 (13 444)
Base case, TRA’s
hospital price (SE)
40 384 (9676) 7568 (525) 32,816 (9695) 1.760 (0.438) 0.596 (0.072) 1.164
a (0.429) 28 192 (11 591)
Undiscounted 44 349 7618 36 732 1.795 0.603 1.192 30 807
UK mSTS ongoing cost data 44 657 7706 36 950 1.755 0.598 1.156 31 951
Death cost data from UK
included
44 764 8138 36 626 1.764 0.595 1.169 31 330
EST: 0% seek EST CT 40 454 4106 36 347 1.764 0.598 1.166 31 162
EST: 20% seek EST CT 42 449 6185 36 264 1.753 0.597 1.156 31 363
EST: 50% seek EST CT 46 180 9295 36 885 1.760 0.595 1.165 31 653
TRA: wholesale/hospital price 40 384 7563 32 821 1.756 0.595 1.161 28 273
TRA: given as outpatient 39 033 5475 33 558 1.754 0.597 1.157 29 005
TRA: 1.5 mg/m
2, BSA 1.7 m
2 49 589 7568 42 021 1.768 0.596 1.172 35 849
TRA: SAE costs doubled 44 526 7571 36 955 1.766 0.597 1.169 31 602
EST: ETO monotherapy 45 097 8420 36 677 1.765 0.599 1.166 31 442
EST: DAC monotherapy 42 201 5912 36 289 1.768 0.598 1.170 31 003
EST: IADIC 45 903 9157 36 746 1.758 0.593 1.165 31 550
EST: IE 47 822 10 991 36 831 1.765 0.597 1.168 31 539
EST: IMVP-6a 45 384 8703 36 681 1.767 0.596 1.171 31 322
EST: on average 2 month
disease stabilisation in both
EST groups
44 581 7775 36 806 1.840 0.629 1.211 30 402
EST alone: on average
2 month disease
stabilisation
44 393 7787 36 606 1.766 0.631 1.135 32 241
EST: 100% active EST; on
average 6 month stabilisation
in EST alone
51 619 15 263 36 357 1.772 0.697 1.075 33 830
CUA: 15D, TRA’s retail
price (SE)
44 395 (11 087) 7559 (509) 36 835 (10 868) 1.302
b (0.332)
b 0.438
b (0.051)
b 0.864
a,b (0.281)
b 42 633
c (18 521)
CUA: 15D, TRA’s hospital
price (SE)
40 384 (9676) 7559 (509) 32 825 (9695) 1.302
b (0.332)
b 0.438
b (0.051)
b 0.864
b (0.281)
b 37 992
c (15 786)
CUA: SF-6D, TRA’s retail
price
44 473 7568 36 905 1.175
b 0.398
b 0.777
b 47 523
c
CUA: SF-6D, TRA’s hospital
price
40 384 7568 32 816 1.175
b 0.398
b 0.777
b 42 234
c
CUA: EQ-5D, TRA’s retail price 44 130 7585 36 545 1.157
b 0.392
b 0.766
b 47 735
c
CUA: EQ-5D, TRA’s hospital
price
40 384 7585 32 799 1.157
b 0.392
b 0.766
b 42 819
c
Pharmacy retail prices without value added tax assumed for trabectedin, if not otherwise stated.
aSigniﬁcant amount of LYGs or QALYs.
bQALY.
cIncremental cost-utility ratio.
BSA, body surface area; CT, chemotherapy; CUA, cost-utility analysis; DAC, dacarbazine; EQ-5D, EuroQol 5D; EST, end-stage treatment; ETO, etoposide;
Incr., increment; IADIC, doxorubicin, ifosfamide, mesna and DAC; ICER, incremental cost-effectiveness ratio; IE, ifosfamide, mesna, ETO, phenobarbital
and growth hormone; IMVP-6a, ifosfamide, mesna, ETO and methotrexate; LYGs, life year gained; mSTS, metastatic soft tissue sarcoma; SAE, serious
adverse event; SE, standard error; SF-6D, Short Form 6D; QALY, quality-adjusted life year; TRA, trabectedin.
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TRA (i.e. usually SD utility > PD utility, but here, SD utility =
PD utility [17, 26, 27]). Nonetheless, TRA demonstrated
potential cost-utility, which could also be acceptable, e.g. in
the UK.
A modelled economic evaluation was essential to capture the
potential costs and beneﬁts associated with TRA / EST and
EST in a therapeutic setting outside the STS-201 [9] and EORTC
STBSG [15, 16]. The STS-201 was aimed at assessing the efﬁcacy
of two different TRA doses. For both STS-201 regimes, the 6-
month PFS rates were considerably greater than, e.g., the 6-
month PFS of 14% reported by van Glabbeke and Verweij [28]
for active regimes in pre-treated patients with STS, and the TRA
results generally [8, 10–12, 29] were consistent. Also the
ifosfamide-based EORTC STBSG [15, 16] data used for the EST
arm were in line with DAC and ETO results [17, 30].
The primary limitation was the use of historical data for EST
arm rather than head-to-head data. Acknowledging the
limitations of historical comparisons, STS-201 survivals
compare favourably with survivals reported for patients after
failure of second-line ifosfamide [15, 16] using the
correspondent eligibility criteria as in STS-201 and for patients
who received DAC [17] or ETO [30] after the failure on
standard CT. Also, the trial-based efﬁcacy and safety of TRA
has been recently conﬁrmed by a compassionate use study [8],
and TRA trials have been found to be well designed [12], which
improved the feasibility of this approach. A randomised data of
TRA against current clinical practice was not available for such
a late cancer stage due to ethical concerns and a lack of
appropriate comparators.
The economic evaluation illustrated the incremental cost-
effectiveness associated with treating mSTS patients who
have failed A/I. The results were within the bounds of what
would usually be considered as good value for money for
a cancer treatment. Before TRA, for mSTS patients no
signiﬁcant therapeutic improvements had occurred over
three decades.
conclusions
TRA was a potentially cost-effective treatment of mSTS patients
who have received priory A/I. In fact, the cost-effectiveness of
TRA was comparable with or superior to many other cancer
drugs for nonorphan conditions. The value of additional
parameter information using equivalent setting and parameter
deﬁnitions is likely to be low.
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appendix 1. The estimation of transition
probabilities
Transition probabilities SD / PD treated with TRA, PD /
death after TRA and PD / death with EST were estimated
using the same principle: the number of months that it took for
‡20% of the population to remain in health state (SD or PD)
was used to calculate the per cycle probabilities of progression
to PD or death. This conservative cut-off ensured that only the
most robust data were used. The outliers who took an
unusually long time to SD / PD relative to the rest of the TRA
population were excluded because the inclusion of these
outliers would distort the transition probabilities and boost the
cost-effectiveness associated with TRA.
TRA / EST arm transition probabilities per cycle (STS-201
24-h q3wk regime)
 Total SD / PD; for 9 months ‡20% remained SD: 0.1578
(i.e. 1 2[(1 2 0.787) (1/9)] = 0.1578; compare Fleurence and
Hollenbeak [1] for the equation). This comprised SD / PD
and SD / death
 SD / death; proportion of patients for whom TTP = OS
multiplied by SD / PD: 0.0070
 SD / PD; SD / death was subtracted from the total SD /
PD: 0.1508
 Remaining PF; complement of the total SD / PD: 0.8422
 PD / death; for 26 months ‡20% remained PD: 0.0573.
EST arm transition probabilities per cycle (EORTC STBSG)
 PD / death; for 11 months ‡20% remained PD: 0.1147
 Remaining PD; complement of PD / death: 0.8853.
Source for Appendix 1
[1] Fleurence RL, Hollenbeak CS. Rates and probabilities in
economic modelling: transformation, translation and
appropriate application. Pharmacoeconomics 2007; 25: 3–6.
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Sources for Appendix 2
[1] Finnish Medicine Tariff. Helsinki, 1/2010.
[2] Hujanen T, Kapiainen S, Tuominen U et al.
Terveydenhuollon yksikko ¨kustannukset Suomessa vuonna
2006, Helsinki: Stakes, 2008.
[3] Purmonen T, Martikainen JA, Soini EJ et al. Economic
Evaluation of Sunitinib Malate in Second-Line Treatment of
Metastatic Renal Cell Carcinoma in Finland. Clin Ther 2008;
30: 382–392.
appendix 3. Quality of life estimation
Disease-speciﬁc EORTC QLQ-C30 scale values [1] were
mapped to 15D, SF-6D and EQ-5D generic quality of life values
(utilities) by multiplying them with coefﬁcients obtained from
the regression models [2]
Resource Unit cost
(2008 €)
Source Units/
cycle
Cycles
TRA treatment
Yondelis 2 · 1m g+ 1 ·
0.25 mg; dexamethasone,
pharmacy Or hospital price
for above (optional base
case scenario)
5236.47 4528.68 [1] 1 5
Administration; laboratory
tests; travelling
a
751.14 [2]
b 15
ETO EST (120 mg/m
2)
Etoposid 20 mg/ml,
3 · 5m l
60.00 [1] 3 6
Administration 679.42 [2]
b 36
Laboratory tests and
travelling
a
66.90 [2]
b 16
DAC EST (250 mg/m
2)
Dadatic 2 · 200 mg + 1
· 100 mg
53.93 [1] 5 6
Administration 679.42 [2]
b 56
Laboratory tests and travelling
a 108.62 [2]
b 16
IADIC EST
Adriamycin 2 mg/ml, 2 · 25
ml; Haloxan 1 g/m
2,2g ;
Uromitexan 100 mg/ml, 40
mg/kg, 2 · 10 ml + 1 · 4 ml;
Dadatic 2 · 200 mg + 1 ·
100 mg
231.75 [1] 1 6
Administration 679.42 [2]
b 56
Laboratory tests and travelling
a 108.62 [2]
b 16
IE EST
Haloxan 1 g/m
2,2g ;
Uromitexan 100 mg/ml, 40
mg/kg, 2 · 10 ml + 1 · 4m l
42.58 [1] 5 6
Etoposid 100 mg/m
2,2 0
mg/ml, 2 · 5m l
40.00 [1] 3 6
Luminaletten 100 mg,
7 · 15 mg
0.85 [1] 6 6
Neulasta 6 mg 1298.08 [1] 1 6
Administration 679.42 [2]
b 56
Laboratory tests and travelling
a 66.90 [2]
b 16
IMVP-a6 EST
Haloxan 1 g/m
2, 2g;
Uromitexan 100 mg/ml, 40
mg/kg, 2 · 10 ml + 1 · 4m l
42.58 [1] 5 6
Etoposid 100 mg/m
2, 20 mg/
ml, 2 · 5m l
40.00 [1] 3 6
Methotrexate 30 m
2, 25 mg/
ml, 3 · 1m l
8.73 [1] 2 6
Administration 679.42 [2]
b 76
Laboratory tests and travelling 33.87 [2]
b 16
Travelling to administration 33.03 [2]
b 26
SAE related to TRA
Treatment and travelling 1472.90 [2]
b 0.054 1
after A/I failure
Ongoing treatment 607.32 [3]
c 1
appendix 2. (Continued)
aTravelling to administration (€33.03) and to laboratory (€6.49).
bIndexed from 2006 to 2008 price level with the factor of 1.0951 obtained
from the Ofﬁcial Statistics Finland.
cIndexed from 2005 to 2008 price level (€3042.44 during 4.98 months;
€607.32 per cycle).
A/I = anthracycline and/or ifosfamide; DAC, dacarbazine; EST, end-stage
treatment; ETO = etoposid; IADIC, doxorubicin, ifosfamide, mesna and
DAC; IE, ifosfamide, mesna, ETO, phenobarbital and growth hormone;
IMVP-6a, ifosfamide, mesna, ETO and methotrexate; SAE = serious adverse
event; TRA, trabectedin.
Tool QLQ-C30 predictor Scale value
a Multiplier
b Outcome
c
15D Physical functioning 63.477 0.00299 0.18980
Global health status 53.526 0.00262 0.14024
Insomnia 27.084 20.00096 20.02600
Cognitive functioning 86.409 0.00198 0.17109
Constant 1.000 0.26114 0.26114
Utility
d 0.73626
SF-6D Social functioning 67.451 0.00082 0.05531
Global health status 53.526 0.00085 0.04550
Emotional functioning 70.577 0.00167 0.11786
Pain 28.972 20.00122 20.03535
Constipation 17.019 20.00110 20.01872
Dyspnoea 8.481 20.00064 20.00543
Constant 1.000 0.50842 0.50842
Utility
d 0.66760
EQ-5D Physical functioning 63.477 0.00508 0.32246
Emotional functioning 70.577 0.00313 0.22091
Global health status 53.526 0.00546 0.29225
Constant 1.000 20.18143 20.18143
Utility
d 0.65419
aWeighted means from Table III in [1].
bBs from Table 3 in [2].
cOutcome = scale value · multiplier.
dSum.
EORTC, European Organisation for Research and Treatment of Cancer;
EQ-5D, EuroQol 5D; SF-6D, Short Form 6D.
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